HUTCHMED (China) (HMDCF) Receivables (2015 - 2026)
HUTCHMED (China)'s (HMDCF) quarterly Receivables came in at $161.6 million in Q2 2026, down 18.24% year-over-year from $197.6 million in Q2 2025, and down 9.5% quarter-over-quarter from $178.5 million in Q4 2025.
Analysis
HUTCHMED (China) (HMDCF) Receivables (2015 - 2026) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Receivables for 12 consecutive years, with $161.6 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Receivables fell 18.24% year-over-year to $161.6 million in Q2 2026; TTM through Jun 2026 was $161.6 million, a 18.24% decrease from a year earlier, with the FY2025 full-year figure at $178.5 million, changed N/A from the prior year.
- Receivables was $161.6 million for Q2 2026 at HUTCHMED (China), down from $178.5 million in the prior quarter.
- Over five years, Receivables peaked at $197.6 million in Q2 2025 and troughed at $8.3 million in Q4 2023.
- A 5-year average of $121.6 million and a median of $156.4 million in 2023 frame the typical range for Receivables.
- Across the five-year window, Receivables soared 395.16% in 2022 and plunged 31.37% in 2023, its largest moves.
- Over 5 years, Receivables stood at $12.1 million in 2022, then slumped by 31.37% to $8.3 million in 2023, then surged by 2128.75% to $184.7 million in 2024, then declined by 3.31% to $178.5 million in 2025, then declined by 9.5% to $161.6 million in 2026.
- The last three Receivables figures came in at $161.6 million (Q2 2026), $178.5 million (Q4 2025), and $197.6 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 210.98 Bn | 196.99 Bn | 7.24 Bn | 10.23 Bn |
| 2 | Gilead Sciences | 181.24 Bn | 178.06 Bn | 6.22 Bn | 5.90 Bn |
| 3 | Vertex Pharmaceuticals | 132.38 Bn | 124.53 Bn | 2.84 Bn | 2.13 Bn |
| 4 | Regeneron Pharmaceuticals | 82.97 Bn | 74.97 Bn | 3.93 Bn | 6.57 Bn |
| 5 | Argenx Se | 61.59 Bn | 56.41 Bn | 1.37 Bn | 1.93 Bn |
| 6 | Moderna | 54.80 Bn | 49.67 Bn | 52.00 Mn | 160.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.09 Bn | 30.78 Bn | 992.69 Mn | 912.74 Mn |
| 8 | Biogen | 31.34 Bn | 30.05 Bn | 1.96 Bn | 1.89 Bn |
| 9 | Roivant Sciences | 30.11 Bn | 30.11 Bn | 1.16 Mn | - |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - | 161.58 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 161.58 Mn |
| Dec 31, 2025 | 178.55 Mn |
| Jun 30, 2025 | 197.63 Mn |
| Jun 30, 2024 | 184.65 Mn |
| Dec 31, 2023 | 8.29 Mn |
| Jun 30, 2023 | 151.16 Mn |
| Dec 31, 2022 | 12.07 Mn |
| Jun 30, 2022 | 78.89 Mn |
| Dec 31, 2021 | -4.09 Mn |
| Jun 30, 2021 | 82.20 Mn |
| Mar 31, 2021 | 53.13 Mn |
| Dec 31, 2020 | -6.65 Mn |
| Jun 30, 2020 | 59.88 Mn |
| Dec 31, 2019 | 36.94 Mn |
| Sep 30, 2019 | 44.57 Mn |
| Jun 30, 2019 | 44.57 Mn |
| Mar 31, 2019 | 44.55 Mn |
| Dec 31, 2018 | 2.41 Mn |
| Jun 30, 2018 | 47.27 Mn |
| Dec 31, 2017 | 7.20 Mn |